No Data
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Buy Recommendation for Cogent Biosciences Amid Unjustified Stock Decline
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
No Data
No Data